NCT04996004 (TTI-621-03) is a Phase 2 clinical trial of Ontorpacept (TTI-621) in Leiomyosarcoma, sponsored by Pfizer.

Who is sponsoring NCT04996004?

NCT04996004 is sponsored by Pfizer.

What drugs are being tested in NCT04996004?

Interventions in NCT04996004: Ontorpacept (TTI-621), Doxorubicin.

What condition does NCT04996004 study?

NCT04996004 studies Leiomyosarcoma.

Is NCT04996004 still recruiting?

NCT04996004 is currently terminated. Last updated 11 December 2024.

Are results published for NCT04996004?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-12-11 · How we verify

NCT04996004: TTI-621-03

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma

Terminated Phase 2 Results posted Last updated 11 December 2024

What this trial tests

Phase 2 trial testing Ontorpacept (TTI-621) in Leiomyosarcoma in 76 participants. Terminated before completion.

Timeline

22 June 2021

Primary endpoint
7 December 2023

7 December 2023

Quick facts

Lead sponsor	Pfizer
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	76
Start date	22 June 2021
Primary completion	7 December 2023
Estimated completion	7 December 2023
Sites	23 locations across United States

Drugs / interventions tested

Ontorpacept (TTI-621) (ontorpacept-tti-621) — full drug profile →
Doxorubicin (doxorubicin) — full drug profile →

Conditions studied

Leiomyosarcoma — all drugs for Leiomyosarcoma →

Sponsor

Pfizer — full company profile →

Who can join

18 and older, any sex, with Leiomyosarcoma. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs: Phase I Primary · From first dose of study treatment (Day 1) up to 30 Days post last dose of study treatment or start of new anti-cancer therapy whichever occurred soonest (maximum treatment exposure for Phase I was 74.1 weeks; maximum follow up to approx. 78.1 weeks)

An adverse event (AE) was any untoward medical occurrence or worsening of a pre-existing medical condition following or during exposure to pharmaceutical product, whether or not considered causally related to product. A serious adverse event (SAE) was an adverse event occurred during any study at any dose of the investigational products that fulfils one or more of following criteria: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth def

Participants with TEAEs

Group	Value	95% CI
Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin	3
Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin	3
Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin	3

Participants with Serious TEAEs

Group	Value	95% CI
Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin	0
Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin	1
Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin	1

Mean Change From Baseline in Blood Pressure at 30 Minutes Post Dose on Cycle 1 Day 1 (C1D1): Phase I Primary · Baseline, 30 minutes post dose on Day 1 of Cycle 1

Blood pressure included diastolic blood pressure (DBP) and systolic blood pressure (SBP). Mean change from baseline to 30 minutes post-dose on C1D1 were reported in this outcome measure. Baseline was defined as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).

DBP

Group	Value	95% CI
Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin	-0.7	± 5.86
Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin	-0.7	± 3.51
Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin	1.0	± 8.72

SBP

Group	Value	95% CI
Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin	1.7	± 8.02
Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin	2.0	± 3.61
Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin	-8.7	± 4.73

Mean Change From Baseline in Blood Pressure at 60 Minutes Post Dose on C1D1: Phase I Primary · Baseline, 60 minutes post dose on Day 1 of Cycle 1

Blood pressure included DBP and SBP. Mean change from baseline to 60 minutes post-dose on C1D1 were reported in this outcome measure. Baseline was defined as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).

DBP

Group	Value	95% CI
Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin	2.3	± 2.08
Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin	0.7	± 3.21
Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin	1.7	± 9.29

SBP

Group	Value	95% CI
Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin	3.0	± 5.00
Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin	-0.7	± 2.89
Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin	-8.3	± 10.12

Mean Change From Baseline in Blood Pressure at 30 Minutes Post Dose on Cycle 1 Day 8 (C1D8): Phase I Primary · Baseline, 30 minutes post dose on Day 8 of Cycle 1

Blood pressure included DBP and SBP. Mean change from baseline to 30 minutes post-dose on C1D8 were reported in this outcome measure. Baseline was defined as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).

DBP

Group	Value	95% CI
Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin	1.3	± 10.02
Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin	2.7	± 5.03
Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin	0.3	± 2.89

SBP

Group	Value	95% CI
Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin	7.0	± 11.36
Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin	5.0	± 6.93
Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin	-7.3	± 7.51

Mean Change From Baseline in Blood Pressure at 60 Minutes Post Dose on C1D8: Phase I Primary · Baseline, 60 minutes post dose on Day 8 of Cycle 1

Blood pressure included DBP and SBP. Mean change from baseline to 60 minutes post-dose on C1D8 were reported in this outcome measure. Baseline was defined as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).

DBP

Group	Value	95% CI
Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin	0.3	± 9.81
Phase I : Ontorpacept 0.7 mg/kg + Doxorubicin	-4.0	± 7.94
Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin	0.7	± 6.51

SBP

Group	Value	95% CI
Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin	3.3	± 9.07
Phase I : Ontorpacept 0.7 mg/kg + Doxorubicin	2.3	± 9.29
Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin	-1.0	± 11.53

Mean Change From Baseline in Blood Pressure at 30 Minutes Post Dose on Cycle 2 Day 1 (C2D1): Phase I Primary · Baseline, 30 minutes post dose on Day 1 of Cycle 2

Blood pressure included DBP and SBP. Mean change from baseline to 30 minutes post-dose on C2D1 were reported in this outcome measure. Baseline was defined as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).

DBP

Group	Value	95% CI
Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin	3.0	± 3.46
Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin	-2.0	± 6.24
Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin	6.5	± 3.54

SBP

Group	Value	95% CI
Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin	4.0	± 5.29
Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin	-5.7	± 6.51
Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin	3.5	± 16.26

Mean Change From Baseline in Blood Pressure at 60 Minutes Post Dose on C2D1: Phase I Primary · Baseline, 60 minutes post dose on Day 1 of Cycle 2

Blood pressure included DBP and SBP. Mean change from baseline to 60 minutes post-dose on C2D1 were reported in this outcome measure. Baseline was defined as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).

DBP

Group	Value	95% CI
Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin	3.0	± 5.20
Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin	-3.7	± 8.02
Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin	11.0	± 1.41

SBP

Group	Value	95% CI
Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin	5.0	± 5.57
Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin	-2.0	± 14.73
Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin	10.5	± 24.75

Mean Change From Baseline in Blood Pressure at 30 Minutes Post Dose on Cycle 3 Day 1 (C3D1): Phase I Primary · Baseline, 30 minutes post dose on Day 1 of Cycle 3

Blood pressure included DBP and SBP. Mean change from baseline to 30 minutes post-dose on C3D1 were reported in this outcome measure. Baseline was defined as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).

DBP

Group	Value	95% CI
Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin	-3.5	± 6.36
Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin	-5.5	± 4.95
Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin	2.0	± NA

SBP

Group	Value	95% CI
Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin	-6.5	± 17.68
Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin	-14.0	± 0.00
Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin	-8.0	± NA

Mean Change From Baseline in Blood Pressure at 60 Minutes Post Dose on C3D1: Phase I Primary · Baseline, 60 minutes post dose on Day 1 of Cycle 3

Blood pressure included DBP and SBP. Mean change from baseline to 60 minutes post-dose on C3D1 were reported in this outcome measure. Baseline was defined as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).

DBP

Group	Value	95% CI
Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin	0.5	± 6.36
Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin	-2.0	± 2.83
Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin	6.0	± NA

SBP

Group	Value	95% CI
Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin	-1.0	± 7.07
Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin	-12.0	± 4.24
Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin	-11.0	± NA

Mean Change From Baseline in Blood Pressure at Safety Follow up: Phase I Primary · Baseline, Safety follow up (up to 30 Days post last dose of study treatment or start of new anti-cancer therapy whichever occurred soonest (maximum treatment exposure for Phase I was 74.1 weeks; maximum follow up to approx. 78.1 weeks)

Blood pressure included DBP and SBP. Mean change from baseline to safety follow up visit were reported in this outcome measure. Baseline was considered as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).

DBP

Group	Value	95% CI
Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin	7.0	± 2.83
Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin	-10.3	± 2.89
Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin	3.0	± 13.08

SBP

Group	Value	95% CI
Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin	13.5	± 14.85
Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin	-15.7	± 10.07
Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin	8.7	± 12.66

Mean Change From Baseline in Body Weight at C3D1: Phase I Primary · Baseline, Day 1 of Cycle 3

Body weight was measured in kilograms (kg). Baseline was considered as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).

Group	Value	95% CI
Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin	0.68	± 0.962
Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin	-3.86	± 2.885
Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin	-1.71	± 0.148

Mean Change From Baseline in Body Weight at Cycle 5 Day 1 (C5D1): Phase I Primary · Baseline, Day 1 of Cycle 5

Body weight was measured in kilograms. Baseline was considered as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).

Group	Value	95% CI
Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin	-0.91	± 0.000
Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin	-2.50	± 5.452
Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin	-2.09	± 1.534

Adverse events — posted to ClinicalTrials.gov

Time frame: From first dose of study treatment (Day 1up to 30 Days post last dose of study treatment or start of new anti-cancer therapy whichever occurs soonest (maximum exposure up to 74.1 and 88 weeks; maximum follow up to approx. 78.1 and 92 weeks for Phase I and II respectively). Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin

Serious: 0/3 (0%)

Deaths: 1/3

Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin

Serious: 1/3 (33%)

Deaths: 2/3

Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin

Serious: 1/3 (33%)

Deaths: 1/3

Phase II: Ontorpacept 0.2 mg/kg + Doxorubicin (Cohort A)

Serious: 9/32 (28%)

Deaths: 12/32

Phase II: Ontorpacept 1.0 mg/kg + Doxorubicin (Cohort C)

Serious: 8/13 (62%)

Deaths: 2/13

Phase II: Ontorpacept 2.0 mg/kg + Doxorubicin (Cohort B)

Serious: 15/22 (68%)

Deaths: 9/22

Serious adverse events (46 terms)

Reaction	System	Phase I: Ontorpacept 0.2 m…	Phase I: Ontorpacept 0.7 m…	Phase I: Ontorpacept 2.0 m…	Phase II: Ontorpacept 0.2 …	Phase II: Ontorpacept 1.0 …	Phase II: Ontorpacept 2.0 …
Febrile neutropenia	Blood and lymphatic system disorders	—	—	—	—	—	—
Sepsis	Infections and infestations	—	—	—	—	—	—
Endocarditis	Infections and infestations	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—
Thrombocytopenia	Blood and lymphatic system disorders	—	—	—	—	—	—
Neutropenia	Blood and lymphatic system disorders	—	—	—	—	—	—
COVID-19	Infections and infestations	—	—	—	—	—	—
Pelvic abscess	Infections and infestations	—	—	—	—	—	—
Staphylococcal bacteraemia	Infections and infestations	—	—	—	—	—	—
Staphylococcal sepsis	Infections and infestations	—	—	—	—	—	—
Wound infection	Infections and infestations	—	—	—	—	—	—
Small intestinal obstruction	Gastrointestinal disorders	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—
Colitis	Gastrointestinal disorders	—	—	—	—	—	—
Enterocolitis	Gastrointestinal disorders	—	—	—	—	—	—
Haemorrhoidal haemorrhage	Gastrointestinal disorders	—	—	—	—	—	—
Lower gastrointestinal haemorrhage	Gastrointestinal disorders	—	—	—	—	—	—
Pancreatitis	Gastrointestinal disorders	—	—	—	—	—	—
Cerebrovascular accident	Nervous system disorders	—	—	—	—	—	—
Aphasia	Nervous system disorders	—	—	—	—	—	—
Hypoaesthesia	Nervous system disorders	—	—	—	—	—	—
Spinal cord compression	Nervous system disorders	—	—	—	—	—	—
Syncope	Nervous system disorders	—	—	—	—	—	—
Cardiac arrest	Cardiac disorders	—	—	—	—	—	—
Cardiac hypertrophy	Cardiac disorders	—	—	—	—	—	—

Other adverse events (65 terms — click to expand)

Reaction	System	Phase I: Ontorpacept 0.2 m…	Phase I: Ontorpacept 0.7 m…	Phase I: Ontorpacept 2.0 m…	Phase II: Ontorpacept 0.2 …	Phase II: Ontorpacept 1.0 …	Phase II: Ontorpacept 2.0 …
Fatigue	General disorders	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—
Platelet count decreased	Investigations	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—
Neutrophil count decreased	Investigations	—	—	—	—	—	—
Infusion related reaction	Injury, poisoning and procedural complications	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—
Alopecia	Skin and subcutaneous tissue disorders	—	—	—	—	—	—
Stomatitis	Gastrointestinal disorders	—	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—
White blood cell count decreased	Investigations	—	—	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—	—	—
Neutropenia	Blood and lymphatic system disorders	—	—	—	—	—	—
COVID-19	Infections and infestations	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—
Dizziness	Nervous system disorders	—	—	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—
Lymphocyte count decreased	Investigations	—	—	—	—	—	—
Pain in extremity	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—
Gastrooesophageal reflux disease	Gastrointestinal disorders	—	—	—	—	—	—
Dry mouth	Gastrointestinal disorders	—	—	—	—	—	—
Abdominal distension	Gastrointestinal disorders	—	—	—	—	—	—
Chills	General disorders	—	—	—	—	—	—
Non-cardiac chest pain	General disorders	—	—	—	—	—	—
Blood alkaline phosphatase increased	Investigations	—	—	—	—	—	—
Dysgeusia	Nervous system disorders	—	—	—	—	—	—
Muscle spasms	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—
Pruritus	Skin and subcutaneous tissue disorders	—	—	—	—	—	—
Dysuria	Renal and urinary disorders	—	—	—	—	—	—
Insomnia	Psychiatric disorders	—	—	—	—	—	—
Dyspepsia	Gastrointestinal disorders	—	—	—	—	—	—
Oedema peripheral	General disorders	—	—	—	—	—	—
Thrombocytopenia	Blood and lymphatic system disorders	—	—	—	—	—	—
Blood bilirubin increased	Investigations	—	—	—	—	—	—

Most-reported serious reactions: Febrile neutropenia, Sepsis, Endocarditis, Anaemia, Thrombocytopenia, Neutropenia, COVID-19, Pelvic abscess.

Data from ClinicalTrials.gov NCT04996004 adverse events section.

Sponsor's own description

The purpose of this study is to learn about the safety and effects of the study medicine (called Ontorpacept or TTI-621) when given alone and when given in combination with doxorubicin for people with leiomyosarcoma. Leiomyosarcoma is a tumor of the smooth muscles. This study is seeking participants who have: * leiomyosarcoma that is advanced or has spread to other parts of the body (metastatic) * not received prior treatment with anthracyclines (a drug commonly used in patients with some kinds of cancer, including leiomyosarcoma) * not received more than one prior treatment for their leiomyosarcoma During the first 18 weeks of this study, participants will receive doxorubicin by IV infusion (given directly into a vein) at the study clinic every 3 weeks for a total of 6 doses. Participants will also receive Ontorpacept (TTI-621) by IV infusion at the study clinic on the same day as doxorubicin and again one week later for the first 18 weeks. After the first 18 weeks, participants will stop receiving doxorubicin but will continue receiving Ontorpacept (TTI-621) as IV infusion every 14 days at the study clinic. They will keep receiving Ontorpacept (TTI-621) until their cancer is no longer responding to treatment. We will examine the experiences of participants receiving Ontorpacept (TTI-621) in combination with doxorubicin in the first 18 weeks and then Ontorpacept (TTI-621) by itself after the doxorubicin is stopped. This will help us determine if the study medicine Ontorpacept (TTI-621) given with doxorubicin and then by itself is safe and effective. Participants will be involved in the study for approximately one year, depending on how their cancer responds to the study treatment. They will have study visits about 12 times in the first 18 weeks (when the study medicine Ontorpacept is given with doxorubicin) and then every two weeks after the doxorubicin is stopped and the study medicine Ontorpacept (TTI-621) is given by itself.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting CD47 for cancer immunotherapy.
Jiang Z, Sun H, Yu J, Tian W, et al · · 2021 · cited 254× · PMID 34717705 · DOI 10.1186/s13045-021-01197-w
Emerging phagocytosis checkpoints in cancer immunotherapy.
Liu Y, Liu Y, Wang Y, Yang Y, et al · · 2023 · cited 186× · PMID 36882399 · DOI 10.1038/s41392-023-01365-z
Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer.
Zeng Z, Fu M, Hu Y, Wei Y, et al · · 2023 · cited 93× · PMID 37853437 · DOI 10.1186/s12943-023-01877-w
Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments.
Xu J, Ding L, Mei J, Hu Y, et al · · 2025 · cited 89× · PMID 40850976 · DOI 10.1038/s41392-025-02325-5
CD47-SIRPα blocking-based immunotherapy: Current and prospective therapeutic strategies.
Bouwstra R, van Meerten T, Bremer E. · · 2022 · cited 82× · PMID 35908284 · DOI 10.1002/ctm2.943
Targeting of TAMs: can we be more clever than cancer cells?
Kzhyshkowska J, Shen J, Larionova I. · · 2024 · cited 79× · PMID 39516356 · DOI 10.1038/s41423-024-01232-z
Nano-Drug Delivery Systems Entrapping Natural Bioactive Compounds for Cancer: Recent Progress and Future Challenges.
Chavda VP, Patel AB, Mistry KJ, Suthar SF, et al · · 2022 · cited 75× · PMID 35425710 · DOI 10.3389/fonc.2022.867655
Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed.
Qu T, Li B, Wang Y. · · 2022 · cited 66× · PMID 35418166 · DOI 10.1186/s40364-022-00373-5

Verify or expand the search:

Other recruiting trials for Leiomyosarcoma

Currently open trials in the same condition.

NCT07169344 — Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma · Phase 2 · recruiting
NCT06528769 — Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma · Phase 2 · recruiting
NCT06975293 — STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants · Phase 1, PHASE2 · recruiting
NCT06849986 — IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS) · Phase 2 · recruiting
NCT06308419 — A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcoma · Phase 1 · recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04996004 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 11 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04996004.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing